Straits Times Index
3,377.65 +11.98 (+0.36%) S&P 500
4,066.79 -9.81 (-0.24%) Dow
33,910.48 -175.56 (-0.52%) Nasdaq
11,566.08 -18.47 (-0.16%) BTC-USD
23,098.92 -29.06 (-0.13%) CMC Crypto 200
523.36 +280.68 (+115.66%)
GILD Feb 2023 65.000 put
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0100 |
| Ask | 0.7500 |
| Strike | 65.00 |
| Expiry date | 2023-02-17 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.1k |
- Business Wire
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
FOSTER CITY, Calif., February 01, 2023--Gilead awards $7.6 million in grants to 24 U.S.-based organizations through the newly created Toward Health Equity Oncology Grant(TM).
- Zacks
Why Gilead (GILD) is Poised to Beat Earnings Estimates Again
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Business Wire
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif., January 30, 2023--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, sa
